<span lang="EN-GB"></span> <font face="Times New Roman" size="3"> </font> <span lang="EN-GB"></span>

 

 

<span lang="EN-GB"></span>

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

Company

Company

Remimazolam

Remimazolam

Media and Investors

Media and Investors

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs for out-patient and hospital-based sedation, anesthesia and critical care services.

 

Learn more About PAION

news

08/12/2020

Consolidated Financial Interim Report for the First Half Year 2020

Consolidated Financial Interim Report for the First Half-Year...

Read more
08/12/2020

PAION AG REPORTS FINANCIAL RESULTS FOR THE FIRST HALF-YEAR 2020

DGAP-News: PAION AG / Key word(s): Half Year Results12.08.2020 /...

Read more
08/11/2020

PAION ANNOUNCES PROGRESS WITH REMIMAZOLAM BY ITS PARTNER YICHANG HUMANWELL IN...

DGAP-News: PAION AG / Key word(s): Miscellaneous11.08.2020 /...

Read more
To the newsroom

PAION Chart

Load Chart

I consent to the display of external content. This enables personal data to be transmitted to third-party platforms. Read more about our privacy policy.

 

Visit us on LinkedIn!
LinkedIn